168 related articles for article (PubMed ID: 12957684)
1. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil HA; Huxley RR; Hawkins MM; Durrington PN; Betteridge DJ; Humphries SE;
Atherosclerosis; 2003 Sep; 170(1):73-8. PubMed ID: 12957684
[TBL] [Abstract][Full Text] [Related]
2. Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
Humphries SE; Cooper JA; Capps N; Durrington PN; Jones B; McDowell IFW; Soran H; Neil AHW;
Atherosclerosis; 2019 Feb; 281():207-212. PubMed ID: 30458964
[TBL] [Abstract][Full Text] [Related]
3. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.
Humphries SE; Cooper JA; Seed M; Capps N; Durrington PN; Jones B; McDowell IFW; Soran H; Neil HAW;
Atherosclerosis; 2018 Jul; 274():41-46. PubMed ID: 29751283
[TBL] [Abstract][Full Text] [Related]
4. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
5. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.
Atherosclerosis; 1999 Jan; 142(1):105-12. PubMed ID: 9920511
[TBL] [Abstract][Full Text] [Related]
6. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
7. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil HA; Hawkins MM; Durrington PN; Betteridge DJ; Capps NE; Humphries SE;
Atherosclerosis; 2005 Apr; 179(2):293-7. PubMed ID: 15777544
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
Nordestgaard BG; Chapman MJ; Humphries SE; Ginsberg HN; Masana L; Descamps OS; Wiklund O; Hegele RA; Raal FJ; Defesche JC; Wiegman A; Santos RD; Watts GF; Parhofer KG; Hovingh GK; Kovanen PT; Boileau C; Averna M; Borén J; Bruckert E; Catapano AL; Kuivenhoven JA; Pajukanta P; Ray K; Stalenhoef AF; Stroes E; Taskinen MR; Tybjærg-Hansen A;
Eur Heart J; 2013 Dec; 34(45):3478-90a. PubMed ID: 23956253
[TBL] [Abstract][Full Text] [Related]
9. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
[TBL] [Abstract][Full Text] [Related]
10. Dutch Lipid Clinic Network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population.
Séguro F; Bongard V; Bérard E; Taraszkiewicz D; Ruidavets JB; Ferrières J
Arch Cardiovasc Dis; 2015 Oct; 108(10):511-8. PubMed ID: 26073227
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia.
Clarke RE; Padayachee ST; Preston R; McMahon Z; Gordon M; Graham C; Crook MA; Wierzbicki AS
Heart; 2013 Feb; 99(3):175-80. PubMed ID: 23213176
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
Rallidis LS; Triantafyllis AS; Tsirebolos G; Katsaras D; Rallidi M; Moutsatsou P; Lekakis J
Atherosclerosis; 2016 Jun; 249():17-21. PubMed ID: 27062405
[TBL] [Abstract][Full Text] [Related]
13. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Neil A; Cooper J; Betteridge J; Capps N; McDowell I; Durrington P; Seed M; Humphries SE
Eur Heart J; 2008 Nov; 29(21):2625-33. PubMed ID: 18840879
[TBL] [Abstract][Full Text] [Related]
14. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
Bruckert E; Kalmykova O; Bittar R; Carreau V; Béliard S; Saheb S; Rosenbaum D; Bonnefont-Rousselot D; Thomas D; Emery C; Khoshnood B; Carrié A
Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
[TBL] [Abstract][Full Text] [Related]
16. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia.
Sijbrands EJ; Westendorp RG; Paola Lombardi M; Havekes LM; Frants RR; Kastelein JJ; Smelt AH
Atherosclerosis; 2000 Apr; 149(2):421-5. PubMed ID: 10729393
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
De Backer G; Besseling J; Chapman J; Hovingh GK; Kastelein JJ; Kotseva K; Ray K; Reiner Ž; Wood D; De Bacquer D;
Atherosclerosis; 2015 Jul; 241(1):169-75. PubMed ID: 25997074
[TBL] [Abstract][Full Text] [Related]
18. Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
Weng S; Kai J; Tranter J; Leonardi-Bee J; Qureshi N
Atherosclerosis; 2018 Jul; 274():54-60. PubMed ID: 29751285
[TBL] [Abstract][Full Text] [Related]
19. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
20. Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
Petrulioniene Z; Gargalskaite U; Kutkiene S; Staigyte J; Cerkauskiene R; Laucevicius A
Atherosclerosis; 2018 Oct; 277():407-412. PubMed ID: 30270078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
